New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
05:45 EDTAZNAstraZeneca announces FDA approval of Epanova
AstraZeneca announced the FDA approved Epanova as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Epanova is the first FDA approved prescription omega-3 in free fatty acid form. The dosage of Epanova is 2 grams or 4 grams, making it the first prescription omega-3 to have a dosing option as few as two capsules once a day. It can be taken with or without food. The FDA approval was based on data from a clinical development program that included positive results from the Phase III EVOLVE trial, which examined the efficacy of Epanova in lowering triglycerides and other key lipid parameters in patients with very high triglycerides. The effect of Epanova on the risk of pancreatitis or on cardiovascular mortality and morbidity has not been determined.
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
07:15 EDTAZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
October 15, 2014
10:48 EDTAZNShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
October 14, 2014
11:23 EDTAZNBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
10:08 EDTAZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 9, 2014
08:10 EDTAZNAstraZeneca reports Phase IIb study of benralizumab met primary endpoint
Subscribe for More Information
October 7, 2014
07:48 EDTAZNSalix reinstated with a Buy at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use